Table 3: Linear regression of patients’ characteristics with LnS100B.

beta95% confidence intervalP

Age-0.057-0.320 -0.2100.960
Female-0.095-0.943-0.4580.502
BMI-0.098-0.063-0.0570.923
Current smoking-2.08-1.314-0.1880.139
CAD0.044-1.712-0.9730.757
Arterial Hypertension0.037-0.617-0.8000.796
MAP-0.187-0.051-0.0100.185
Duration of diabetes0.105-0.002-0.0040.459
MDRD-0.202-0.030-0.0050.150
HbA1c0.072-0.211-0.3570.610
TNF-a-0.135-0.700-0.1990.341
Insulin0.026-0.767-0.9200.856
Metformin0.092-0.484-0.9510.516
DPP4 inhibitors-0.072-0.987-0.5870.613
Sulphonylureas-0.056-0.896-0.6010.694
ACE/ARBs-0.027-0.729-0.6020.849
b-blockers0.0980.470-0.9640.492
Antiplatelet treatment0.113-0.423-0.9850.426
Statin treatment0.169-0.261-1.0540.232
Depressive symptoms0.084-0.470-0.8710.552
Hamilton score0.019-0.098-1.1120.894
Zung self-assessment score0.048-0.024-0.0330.738

BMI: body mass index, TIA: transient ischemic attack, CAD: cardiovascular disease, MAP: Mean Arterial Pressure (MAP = [(2 x diastolic)+systolic]/3, MDRD: GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) (mL/min/1.73 m2), HbA1c: glycated hemoglobin, TNFa: tumor necrosis factor a, S100B: S100 calcium binding peptide b, DPP4 inhibitors: dipeptidyl-peptidase 4 inhibitors, ACE: angiotensin-converting-enzyme inhibitor, and ARBs: angiotensin receptor blockers.